| Number | 21816 |
| Subject | Business |
| Source | HarperCollins (New York) |
| State | NY |
| Year | 2004 |
| Publication Date | Jan. 20, 2004 |
| Summary | This book is a behind-the-scenes look at ImClone and the biotech company's CEO, Sam Waksal. ImClone's drug Erbitux promised a revolutionary way to treat cancer. Bristol-Myers Squibb signed an unprecedented $2 billion deal to market the drug. Waksal lived a life of luxury. But by late December 2001 the FDA rejected Erbitux because ImClone's science was "sloppy" and "incomplete." Waksal tried to cash in before his stock plummeted on the news. He forged signatures and traded his family's shares on inside information, an unfolding scandal that also ensnared Martha Stewart, a friend of Waksal. He is now in jail. |
| Category | Contest Entry |
| Pages | 4 |
| Keywords | BOOK;ImClone;Erbitux;Waksal;cancer drug;insider trading;FDA;SEC;DOJ |
| Related Links | |
| Related Video | |
| Contest Questionnaires | Only members can download contest entry questionnaires! Log in to get access. |
| Ordering info | Want to place an order? Email us or call us at 573-882-3364 (Stories are only available to members of IRE. For membership information, please refer to our membership page) |